Cancer

Multi-Cancer Early Detection Test Added to Evexia Diagnostics Platform

20/20 BioLabs’ AI-powered multi-cancer early detection test, OneTest for Cancer, is now available to approximately 40,000 clinicians via the Evexia Diagnostics platform.

New Research on Automated Myeloid Testing and Molecular Residual Disease to be Presented at AACR 2026
DecisionDx-Melanoma Gene Expression Test Improves Risk Prediction Beyond Standard Staging
EpiCapture Urine-Based Prostate Cancer Test Shows High Accuracy in Clinical Study
Home HPV Self-Sampling Kits Show Promise for Closing Cervical Screening Gap in Disabled Women
Urine-Based Liquid Biopsy Shows High Sensitivity for Prostate Cancer Detection
New Whole Genome and Transcriptome Assay Launches for Myeloid Malignancies
Blood Test Using Inflammatory Biomarkers Advances for Colorectal Cancer Detection
Molecular Test Detects Bile Duct Cancer at Twice the Rate of Standard Methods
New AI Test Estimates Individualized Chemotherapy Benefit in Breast Cancer Patients

Cancer

Lunit, CellCarta Partner to Advance AI-Powered Digital Pathology for Companion Diagnostics

The collaboration pairs AI pathology algorithms with global laboratory infrastructure to help biopharma teams speed up evidence generation and diagnostic launch timelines.

Cancer

Largest Lung Nodule Biomarker Validation Study Backs Earlier Cancer Detection

A pooled analysis of more than 1,100 patients across four cohort studies supports the clinical utility of the Nodify CDT test in identifying high-risk lung nodules.

Walgreens Partners to Expand Colorectal Cancer Screening Access

Mar 13, 2026 | Colorectal

The initiative gives eligible pharmacy customers a streamlined pathway to request the Cologuard stool DNA test, with no prep or special diet required.

Hepion Pharmaceuticals Licenses ctRNA Biomarker Assay for Liver Cancer Detection

Mar 13, 2026 | Cancer

Hepion Pharmaceuticals has licensed a circulating tumor RNA assay from Cirna Diagnostics for early detection of hepatocellular carcinoma in high-risk patients, expanding its liquid biopsy portfolio for liver cancer.

Protein Biomarker Tests May Detect Cancer Earlier Than DNA-Based Methods

Mar 12, 2026 | Cancer

20/20 BioLabs argues a tiered screening approach—starting with protein-based tests before moving to circulating tumor DNA testing or imaging—could improve early-stage detection and lower costs.

Study Finds Multi-Omic Breast Cancer Test Predicts Radiation Therapy Benefit

Mar 12, 2026 | Breast

Data show the test can predict both locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.

Guardant’s Shield CRC Blood Test Now Orderable Through Quest Diagnostics Network

Mar 11, 2026 | Colorectal

Physicians can now order the Shield blood test through Quest’s network of nearly 650,000 clinician and hospital accounts, patient service centers, and in-office phlebotomists.

Study Shows Dual Epigenetic Markers Improve Early Colorectal Cancer Detection

Mar 9, 2026 | Colorectal

A study reports that dual epigenetic markers in cell-free DNA achieved 95% diagnostic accuracy for stage I colorectal cancer, outperforming conventional liquid biopsy methods.

FDA Grants Breakthrough Status to Breath Test for Postoperative Pneumonia Risk

Feb 27, 2026 | Cancer, Cardiovascular, Diagnostic Technologies, Mass Spectrometry

The FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.’s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.

Fecal DNA Methylation Test Shows Promise for Colorectal Cancer Screening

Feb 27, 2026 | Colorectal

A multicenter study reports that combining fecal SDC2 methylation testing with the APCS scoring system improves advanced adenoma detection and specificity in colorectal cancer screening.

Blood Test Could Enable Earlier Detection of Gallbladder Cancer

Feb 27, 2026 | Cancer

Researchers have identified blood-based metabolic signatures that may enable earlier, noninvasive detection of gallbladder cancer, according to findings in the Journal of Proteome Research.

Veracyte Presents 15 Studies on Decipher Cancer Tests at ASCO GU Symposium

Feb 26, 2026 | Prostate

Veracyte will present over 15 studies on its Decipher prostate and bladder cancer tests, including new clinical trial data, at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco.

NeoGenomics Launches PanTracer Pro for Solid Tumor Testing

Feb 26, 2026 | Cancer, Diagnostic Technologies, Molecular Diagnostics

The integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.

Three-Year NHS Study Shows Blood Test Reduces Stage IV Cancer Diagnoses

Feb 24, 2026 | Cancer, Diagnostic Technologies, Molecular Diagnostics

The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.

ClearNote Health Launches Enhanced Pancreatic Cancer Blood Test

Feb 23, 2026 | Pancreatic

ClearNote Health has launched an enhanced pancreatic cancer test, reporting 82.6% sensitivity and 97.5% specificity in high-risk patients using a multianalyte, multiomic blood-based approach.

Personalis Receives Medicare Coverage for NeXT Personal in Lung Cancer Surveillance

Feb 18, 2026 | Lung Cancer

The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.

Guardant Health Offers Free Colorectal Cancer Screening Tests Through Community Grant Program

Feb 18, 2026 | Colorectal

Guardant Health will provide up to 100 free Shield blood tests per organization to support colorectal cancer screening events and outreach during Colorectal Cancer Awareness Month in March.

Category: Cancer

Cancer

Cancer

Cancer